Table 1.
Summary of Baseline Characteristics
| Norditropin NordiFlex (n = 8) | NNC0195-0092 (mg/kg) |
||||
|---|---|---|---|---|---|
| 0.02 (n = 7) | 0.04 (n = 6) | 0.08 (n = 6) | 0.12 (n = 7) | ||
| Age, y | 57.0 (14.9) | 51.6 (12.2) | 56.8 (13.1) | 55.3 (12.8) | 43.3 (16.9)a |
| Sex, M/F | 6/2 | 7/0 | 3/3 | 3/3 | 6/1 |
| Body weight, kg | 81.4 (17.0) | 84.1 (15.3) | 88.3 (16.6) | 77.8 (23.2) | 80.1 (15.3) |
| BMI, kg/m2 | 26.8 (3.7) | 27.3 (2.7) | 30.0 (4.1) | 25.5 (4.7) | 25.9 (4.6) |
| GHD onset | |||||
| Childhood, idiopathic | 0 (0) | 2 (28.6) | 0 (0) | 0 (0) | 1 (14.3) |
| Childhood, acquired | 1 (12.5) | 1 (14.3) | 1 (16.7) | 2 (33.3) | 2 (28.6) |
| Adult | 7 (87.5) | 4 (57.1) | 5 (83.3) | 4 (66.7) | 4 (57.1) |
Abbreviation: BMI, body mass index. Data are presented as mean (SD).
a
Mean age of subjects in the 0.12-mg/kg group was below the mean age of trial subjects (52.7 [14.3] y).